ASCVD Risk Hit Hard by COVID-19: A Lipidologist's View

Preventive cardiology and lipid specialist Seth J. Baum, MD, answers questions about the state of preventive cardiology in the midst of COVID-19.

Seth J. Baum, MD, discusses the "state of ASCVD risk assessment" in 2020 and highlights the potential COVID-19-related setbacks in cardiovascular health as healthy activity is limited, cooking and eating are ever-present in the media, and many individuals with chronic conditions, including hypertension, congestive heart failure, ACS, remain reluctant to make in-person appointments for follow-up.

Dr Baum is clinical professor, biomedical science, at the Florida Atlantic University Charles E. Schmidt College of Medicine; he is founder and chief medical officer of Excel Medical Clinical Trials, LLC, and past president of the American Society for Preventive Cardiology. He is in private practice i Boca Raton, FL, where he specializes in lipid disorders and cardiovascular disease prevention.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.